Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 28

Evogene, Tel Aviv University Launch AI Drug Discovery Initiative

Jul 9, 2026
Evogene has partnered with Tel Aviv University’s Blavatnik Center for Drug Discovery to establish a joint initiative aimed at accelerating small-molecule drug discovery programmes…
Read More...

Wainua Misses Primary Endpoint in ATTR-CM Phase III Trial

Jul 9, 2026
AstraZeneca and Ionis Pharmaceuticals have announced that their Phase III CARDIO-TTRansform trial evaluating Wainua (eplontersen) in patients with transthyretin-mediated amyloid…
Read More...

OTR Therapeutics, LG Chem Partner on China Oncology Assets

Jul 9, 2026
OTR Therapeutics has entered into a strategic collaboration with LG Chem to identify, evaluate and develop novel oncology assets originating from China, as both companies seek to expand…
Read More...

Bayer Launches Clinical Trials Alliance With Colorado Health Partners

Jul 9, 2026
Bayer has formed a strategic clinical trials alliance with the University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, marking the company’s first collaboration of…
Read More...

Certara Partners With NVIDIA on Agentic AI Drug Development

Jul 9, 2026
Certara, Inc. has announced a collaboration with NVIDIA aimed at expanding the use of agentic artificial intelligence across drug discovery and development workflows. The partnership…
Read More...

Cyllene Raises €33m to Advance Neurogenic Bladder DNA Medicine

Jul 8, 2026
Cyllene Therapeutics has closed a €33 million Series C financing round to advance clinical development of its lead DNA medicine candidate, EG110A, for severe neurogenic bladder…
Read More...

Biocytogen and Whitehawk Partner on Bispecific ADC Development

Jul 8, 2026
Biocytogen and Whitehawk Therapeutics have entered into a global collaboration to develop bispecific antibody-drug conjugates, expanding efforts to apply dual-targeting antibody…
Read More...

FDA Grants Rare Pediatric Disease Status to Vanda’s CMT2S Therapy

Jul 8, 2026
Vanda Pharmaceuticals has received Rare Pediatric Disease Designation from the US Food and Drug Administration for VCA-894A, an investigational antisense oligonucleotide therapy being…
Read More...

Vivani, Novo Nordisk Partner on Semaglutide Weight-Loss Implant

Jul 8, 2026
Vivani Medical has entered into a new agreement with Novo Nordisk that will allow the Danish drugmaker to evaluate Vivani’s NPM-139 semaglutide implant, a long-acting treatment…
Read More...

Biocytogen, Whitehawk Collaborate on Bispecific ADCs

Jul 8, 2026
Biocytogen and Whitehawk Therapeutics have entered into a global collaboration to develop bispecific antibody-drug conjugates, or BsADCs, for cancer treatment. Under the agreement,…
Read More...
Previous 1 … 26 27 28 29 30 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.